Healthcommunities.com
Home Search SiteMap Forum Store Physician Board How to Quit Smoking Center

Multisystem Atrophy


Multisystem Atrophy Overview

Physician-developed and -monitored.

Original Date of Publication: 02 Jan 2000
Reviewed by: Stanley J. Swierzewski, III, M.D.
Last Reviewed: 04 Dec 2007

Original Source: http://www.neurologychannel.com/msa/index.shtml

Home » Multisystem Atrophy » Multisystem Atrophy Overview


Facebook Twitter

Multisystem Atrophy Overview



Multisystem atrophy (MSA) is a group of rare, multisystem degenerative diseases that have several clinical features of Parkinson's disease and are sometimes referred to as the "Parkinsonism-plus syndromes."

When MSA was first identified in 1960, it was named "Shy-Drager Syndrome" after the two physicians who first described its symptoms. Now, Shy-Drager Syndrome is recognized as one of three manifestations of multisystem atrophy. The other two are striatonigral degeneration and olivopontocerebellar atrophy (OPCA). The three are classified together because of their clinical overlap and neuroanatomical similiarities.

Multisystem atrophy has three cardinal features:

All three characteristics occur in the majority of MSA cases, but with considerable variation with regards to specific attributes, and any one of the three may predominate. If autonomic failure predominates, MSA is known as Shy-Drager Syndrome. If parkinsonism predominates, it is known as striatonigral degeneration. Striatonigral degeneration is usually indistinguishable from Parkinson's disease, except that it does not respond to Parkinson's treatment. If cerebellar ataxia predominates, MSA is known as olivopontocerebellar atrophy (OPCA).



Although cognitive dysfunction may appear minimal, most patients do experience frontal system impairment and many develop dementia late in the course of the disease. MSA is generally more severe than Parkinson's. More than 40% of MSA patients are confined to a wheelchair or otherwise severely disabled within 5 years of initial diagnosis. Except in a few cases, the drug of choice for Parkinson's patients (levedopa) has no effect on MSA and may even worsen symptoms.

Incidence and Prevalence
MSA affects men twice as often as women. The average age of onset is 50 years old, and the average survival time after initial diagnosis is 10 years. As many as 10% of Parkinson's cases that are diagnosed incorrectly are identified as MSA upon autopsy.


Facebook Twitter

© 1998-2010 Healthcommunities.com, Inc. All Rights Reserved.



Multisystem Atrophy (continued...)

Comment on the above article

Browser Comments
    There are currently no comments.

Multisystem Atrophy Resources

Join Our Multisystem Atrophy Forum

Do you have a question, want to share medical advice, or just need to discuss your situation with someone else having a similar experience?

The healthchannels forum is a resource for everyone to share and discuss their health and medical needs with others.



Living with...Share your story

Do you have a personal health story that you would like to share with others?

As a source of free patient education, our goal is to provide our users with trustworthy information and support from others. That's why we've started our "Living with..." sections.

Our "Living With..." support pages are a place to share experiences about living with a certain condition, disease, disorder, or illness and for loved ones of those dealing with health-related issues.

Many people, especially when newly diagnosed, find comfort in knowing that others are having a similar experience.

Help others by sharing your story.

View stories already submitted.

Stay Updated

Sign up for our newsletter and receive important updates on the medical conditions that are most important to you.


To quickly access health information from your website's browser,
download Healthcommunities.com's healthchannels toolbar.


Home